“We are pleased to inform you that MedQuímica Indústria Farmacêutica, Brazil, wholly owned subsidiary of the company, has signed definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.,” Lupin said in a BSE filing.
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for the central nervous system related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix for topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease. “This move reinforces our commitment to making healthcare solutions accessible to all patients,” Lupin said.
“The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” said Alexandre Franca, Managing Director, MedQuímica. “This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market,” he added.
At 10.31 am, the scrip was trading 2.5% higher at Rs 752 over its previous day’s closing price of Rs 733.7 per share. The stock has risen nearly 22% in the last six months, while it has fallen about 20% year-to-date.
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price